Product logins

Find logins to all Clarivate products below.


Overactive Bladder | Treatment Algorithms | Claims Data Analysis | US | 2019

Overactive bladder is a common condition that manifests as a complex set of symptoms in the lower urinary tract and affects both men and women. It is characterized by sudden urges to urinate and may be accompanied by urinary incontinence, urinary frequency, and/or nocturia (nighttime waking to void the bladder). In addition to possible lifestyle changes and/or behavior interventions to help manage overactive bladder, a step-up approach to treatment is generally followed. It typically begins with antimuscarinics, before progressing to more-potent drugs, such as the beta3 adrenergic receptor agonist Myrbetriq (Astellas) or the injectable neurotoxin Botox (Allergan).

QUESTIONS ANSWERED

  •  What patient shares do key therapies and brands garner by line of therapy in newly diagnosed overactive bladder patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed overactive bladder patients?
  •  How have Myrbetriq and Botox been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of overactive bladder patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of overactive bladder patients are treated with monotherapy versus combination therapy? What are the most common combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geographies

United States

Real-world data

Longitudinal patient-level claims data analysis

Key drugs covered

Botox, Myrbetriq, oral oxybutynin, tolterodine tartrate, trospium chloride, Vesicare

Key analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…